EP4088714A1 — Ophthalmic pharmaceutical composition comprising atropine
Assigned to Warszawskie Zaklady Farmaceutyczne Polfa SA · Expires 2022-11-16 · 4y expired
What this patent protects
The present invention is related to a preservative free ophthalmic low concentration atropine sulfate composition containing atropine sulfate in an amount from about 0.005 w/w% to about 0.05 w/w%, citrate buffer, a tonicity agent and water, having a pH from about 4.0 to about 5.5…
USPTO Abstract
The present invention is related to a preservative free ophthalmic low concentration atropine sulfate composition containing atropine sulfate in an amount from about 0.005 w/w% to about 0.05 w/w%, citrate buffer, a tonicity agent and water, having a pH from about 4.0 to about 5.5. Optionally this composition can also contain other excipients such as a pH adjuster, a chelating agent, a complexing agent, and/or a viscosity agent. The invention also relates to a process for the preparation of this composition and its use in the treatment and/or prevention of myopia, preferably in a paediatric population.
Drugs covered by this patent
- Decadron (dexamethasone) · Generic (originally Merck)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.